{"id":"NCT02263131","sponsor":"Il-Yang Pharm. Co., Ltd.","briefTitle":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children","officialTitle":"Randomized, Double Blind, Active-controlled, Phase â…¢ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-01","completion":"2014-06","firstPosted":"2014-10-13","resultsPosted":"2015-04-06","lastUpdate":"2020-07-09"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"IL-YANG FLU Vaccine Prefilled Syringe INJ.","otherNames":[]},{"type":"BIOLOGICAL","name":"VAXIGRIP Prefilled Syringe INJ.","otherNames":[]}],"arms":[{"label":"IL-YANG PFS","type":"EXPERIMENTAL"},{"label":"TIV PFS","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.","primaryOutcome":{"measure":"Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion","timeFrame":"up to Day28(+7)","effectByArm":[{"arm":"IL-YANG PFS","deltaMin":62.02,"sd":null},{"arm":"TIV PFS","deltaMin":76.81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":347},"commonTop":["Tenderness","Pain","Redness","Swelling"]}}